Suggesting acceptable risk-benefit for most 2 Novel but manageable: Unlike severe GI effects that drive discontinuation, this appears more nuisance than barrier 3 Transparency matters: Patients deserve full information, both the 29% weight loss potential and the 20% chance of mild sensory symptoms The Bottom Line Retatrutide may revolutionise obesity treatment
CrossRef Association Between Nonalcoholic Fatty Liver Disease and Future Deterioration of Metabolic Health: A Cohort Study YouCheol Hwang, HongYup Ahn, CheolYoung Park Obesity.2019
(2025), published in Pharmaceuticals, which examined angiogenesis and nitric-oxide mechanism proposals across the published literature [16]
Evidence quality: In vitro + animal models (extensive), with supportive clinical observations in EPP and acne
GLP-1 receptor agonist medications require a prescription and can be expensive
However, many individuals continue to experience residual cravings, emotional dysregulation, and relapse despite these interventions